The FDA called off a meeting of outside advisers who were set to decide Thursday whether to grant approval recommendation for Merck's sugammadex, an injectable drug designed to reverse the effects of muscle relaxants during surgery. Merck said the agency asked for more time to evaluate clinical data linking the drug to allergic reactions.

Full Story:

Related Summaries